Hope for Pancreatic Cancer: The Experimental Drug Turning Heads at ASCO

The trial, known as RASolute 302, tested daraxonrasib against chemotherapy in 500 people with metastatic pancreatic cancer whose disease had progressed after one earlier round of treatment. The central result is the one that drew the headlines: patients taking daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those receiving chemotherapy, according to the American Society of Clinical Oncology. Investigators reported that the drug cut the risk of death by roughly 60%.

To appreciate why those figures landed, it helps to know the backdrop. With existing second-line chemotherapy — the treatment given when a first approach stops working — median overall survival has typically been around six to seven months. Doubling that, in a disease this stubborn, is not a routine result.

What "Median Survival" Really Means

Because the emotions around pancreatic cancer run high, one piece of plain language matters more than almost any other here: a median is a midpoint, not a personal prognosis. A median survival of 13.2 months means about half the patients on daraxonrasib lived longer than that and half lived less. It is a way of describing how a whole group fared, not a prediction for any one person, and longer follow-up will be needed to see how many patients live well beyond that midpoint.

Survival was the headline, but it was not the only measure that moved. Daraxonrasib also delayed the point at which the cancer started growing again — what doctors call progression-free survival — and shrank tumors more often than chemotherapy did. Just as meaningful for daily life, people taking the pill reported less pain and a better quality of life on average than those on chemotherapy, according to the trial summary published by ASCO's patient research team.

Here is how the two approaches compared at a glance:

The pattern is consistent: more benefit, and fewer of the most serious side effects, with the experimental pill — the kind of result that, in this case, earned a standing ovation at the meeting.

To understand why specialists call this a milestone rather than just a good trial, you have to meet the villain of the story: a protein called KRAS. More than 90% of pancreatic ductal adenocarcinomas — the type behind the vast majority of pancreatic cancers — are driven by a KRAS gene mutation that leaves this protein stuck in the "on" position, relentlessly signaling the cancer to grow. For years KRAS was considered nearly impossible to drug, with no approved therapies that directly switched it off in pancreatic cancer.

Daraxonrasib, developed by Revolution Medicines, takes a different approach from earlier attempts. It is an oral, once-daily drug described as a RAS(ON) multi-selective inhibitor — meaning it is designed to switch off the active KRAS protein across several different mutations rather than targeting just one, part of a broader push by Revolution Medicines to make this long-elusive target treatable. There is also a practical difference patients feel directly: daraxonrasib is a pill taken at home, while the comparison chemotherapy regimens are given intravenously in a clinic.

That combination — a hard-to-hit target, finally hit, with a pill — is why ASCO expert Rachna Shroff, MD, called the findings "landscape-changing" and "proof of principle that targeting KRAS in pancreatic cancer is feasible and effective." The trial's principal investigator, Brian Wolpin, MD, MPH, of Dana-Farber Cancer Institute, put the human scale of it plainly: "A median survival of more than a year in the second-line setting really does get your attention."

Measured hope means holding the promise and the caveats together, and daraxonrasib has real caveats. The drug is not gentle. Its most common significant side effects were skin rash and mouth sores, with diarrhea also reported, and oncologists have been candid that these can be challenging and need proactive management. Colin Weekes, MD, PhD, of Mass General Brigham, captured the balance when he said it is "a new day for pancreas cancer" while cautioning that "it's not a benign drug" and that its toxicities "can be problematic" and must be managed — a particular concern for patients treated outside large cancer centers.

There are evidence limits worth keeping in view, too. RASolute 302 followed patients for a median of only about eight to nine months, so the long-term picture is still coming into focus. The benefit was demonstrated specifically in the second-line setting — after an earlier treatment had stopped working — and its role earlier in the disease is still being studied.

The drug is now moving through the steps that could eventually bring it to patients. The FDA has granted daraxonrasib Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12 mutations and Orphan Drug Designation for pancreatic cancer, and selected it for a federal priority-review pilot, with the company stating it plans to submit the RASolute 302 data to support a marketing application. These designations signal that regulators see a promising therapy for a serious unmet need — but they are not the same as approval.

Researchers are also pushing daraxonrasib earlier in treatment. An ongoing phase 3 trial, RASolute 303, is testing it as a first-line therapy, alone and combined with chemotherapy, and the drug is being explored in other cancers driven by RAS mutations. As the U.S. National Library of Medicine's clinical trials registry documents, this is one piece of a fast-moving research program rather than a final answer.

For now, what happened at ASCO 2026 is best understood as a turning point with a road still ahead. After decades in which pancreatic cancer resisted nearly everything, researchers reported that a once-daily pill helped people live meaningfully longer with fewer of the harshest side effects — by switching off a target once thought untouchable. That is real reason for hope, held steadily, with eyes open to the work that remains.